Prevalence of antiretroviral drug resistance in treatment-naive injecting drug users infected with HIV-1 in Guangzhou, 2008-2015.
10.3760/cma.j.issn.0254-6450.2019.02.014
- Author:
L Q XU
1
;
Z G HAN
2
;
Y L ZHANG
1
;
H WU
3
;
K GAO
3
;
Q M LI
3
;
H F XU
3
;
Y S CAI
3
;
Y XIA
1
Author Information
1. School of Public Health, Guangdong Pharmaceutical University, Guangzhou 510310, China.
2. Department of Operational Control, Guangzhou Municipal Center for Disease Control and Prevention, Guangzhou 510440, China.
3. Department of AIDS Control and Prevention, Guangzhou Municipal Center for Disease Control and Prevention, Guangzhou 510440, China.
- Publication Type:Journal Article
- Keywords:
Drug resistance;
HIV;
Injecting drug user
- MeSH:
Adolescent;
Adult;
Child;
Drug Resistance, Viral/genetics*;
Drug Users;
Genes, pol/genetics*;
Genotype;
HIV Infections/psychology*;
HIV-1/isolation & purification*;
Humans;
Male;
Mutation;
Prevalence;
RNA, Viral/genetics*;
Young Adult
- From:
Chinese Journal of Epidemiology
2019;40(2):196-201
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To understand the prevalence of drug resistance in treatment-naive injecting drug users (IDUs) infected with HIV-1 in Guangzhou. Methods: HIV-1 RNA were extracted from the serum specimens of the newly confirmed HIV-1 positive IDUs living in Guangzhou, being infected through injecting drug use and receiving no antiretroviral therapy at the time of confirmation during 2008-2015. Full sequence of pol protease (PR) gene and partial sequence of reverse transcriptase (RT) gene were amplified by nested reverse transcription polymerase chain reaction (nested-PCR) and sequenced. After that, data were submitted to the HIV resistance database of Stanford University for drug resistance analysis. Results: Among the 518 HIV-1 infected IDUs, HIV-1pol gene segments were successfully obtained from the serum samples of 407 HIV-1 infected IDUs (78.57%) aged 18-64 (37.44±8.14) years. Among them, males accounted for 89.68% (365/407), those of Han ethnic group accounted for 89.93% (366/407), the unmarried accounted for 55.28% (225/407), and those with education level of junior high school or below accounted for 83.78% (341/407). The distribution of subtypes was predominated by CRF07_BC (47.18%, 192/407), followed by CRF01_AE (23.83%, 97/407), CRF08_BC (22.85%, 93/407), and other subtypes (6.14%, 25/407). The overall prevalence of drug resistance was 3.44% (14/407). The prevalence of drug resistance to protease inhibitors, nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors were 1.47%(6/407), 0.25% (1/407) and 1.72% (7/407) respectively. The mutation rate was 12.29% (50/407). No major drug resistance mutation was detected in protease and nucleoside reverse transcriptase regions. Higher rate of V179E mutation in the non-nucleoside reverse transcriptase region was detected in other subtypes and subtype CRF07_BC. Mutation seemed to have occurred in all 8 cases of subtype CRF55_01B in other subtypes. The highest mutation rate of E138A was detected in subtype CRF08_BC (3.23%). Two cases were resistant to all four drugs of NNRTIs. Conclusions: The prevalence of drug resistance in treatment-naive HIV-1 positive IDUs remained at a relatively low level during 2008-2015, in Guangzhou. Most infections were sensitive to existing antiviral drugs. However, drug resistance surveillance in IDUs infected with HIV should be strengthened to prevent the prevalence of multi-drug resistance and cross drug resistance.
